On December 16, 2025, Tvardi Therapeutics, Inc. approved one-time retention compensation for key executives, including stock options totaling 82,500 shares, to enhance performance as the company advances its clinical trials. A new Severance Plan was also established to provide severance benefits for eligible employees during and after a Change in Control.